Cypherpunk Technologies Inc.
CYPH · Nasdaq · United States
Share price · CYPH
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CYPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026-19.7%
Nothing announced by CYPH that day or the session before.
- 18 Sep 2026+17.3%
Nothing announced by CYPH that day or the session before.
- 17 Sep 2026+25.8%
Nothing announced by CYPH that day or the session before.
- 3 Sep 2026+35.1%
- Day beforeOther material event
- 19 Aug 2026+32.9%
- 15 Jun 2026+25.0%
Nothing announced by CYPH that day or the session before.
- 8 Jun 2026+36.5%
Nothing announced by CYPH that day or the session before.
- 5 Jun 2026-47.1%
Nothing announced by CYPH that day or the session before.
- 4 Jun 2026-16.8%
Nothing announced by CYPH that day or the session before.
- 2 Jun 2026+13.3%
Nothing announced by CYPH that day or the session before.
Share of unusual movement by asset
For each asset, the share of CYPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 82% |
| Sessions with no dated event | — | 18% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | DKK1 (Dickkopf-1)Monoclonal antibody | Colorectal Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0.2M | $7.6M | —-$2.7M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $0.2M | $6.7M | $77M-$3.4M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.3M | $9.7M | $3.3M-$8.3M operating cash flow | report ↗ |
| 2025-Q2 | — | $11M | $18M | $17M-$14M operating cash flow | report ↗ |
| 2025-Q1 | — | $13M | $33M | $15M-$14M operating cash flow | report ↗ |
| 2024-Q3 | — | $15M | $63M | $18M-$16M operating cash flow | report ↗ |
| 2024-Q2 | — | $18M | $78M | $20M-$14M operating cash flow | report ↗ |
| 2024-Q1 | — | $11M | $55M | $14M-$16M operating cash flow | report ↗ |
| 2023-Q3 | — | $12M | $81M | $14M-$10M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $91M | $13M-$10M operating cash flow | report ↗ |
| 2023-Q1 | — | $39M | $102M | $42M-$13M operating cash flow | report ↗ |
| 2022-Q3 | — | $12M | $78M | $15M-$12M operating cash flow | report ↗ |
| 2022-Q2 | — | $14M | $91M | $17M-$12M operating cash flow | report ↗ |
| 2022-Q1 | — | $7.8M | $103M | $10M-$12M operating cash flow | report ↗ |
| 2021-Q3 | $0.4M | $10M | $125M | $11M-$8.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $26M | $14M | —-$44M operating cash flow | report ↗ |
Leap Therapeutics, Inc. reported R&D spend of $25.67M, down 55.1% YoY, cash and equivalents of $14.04M, and net income of $4.82M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($932K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-12 | Winklevoss Capital Fund, LLC; Winklevoss Treasury Investments, LLC; Winklevoss Tyler Howard; Winklevoss Cameron Howard; Winklevoss Capital Management, LLC · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Option exercise | 4,938,801 | $0.00 | $5K | Form 4 |
| 2026-10-12 | McEvoy William Patrick III · director, Chief Investment Officer, 10% owner | Option exercise | 4,938,801 | $0.00 | $5K | Form 4 |
| 2026-10-12 | Winklevoss Capital Fund, LLC; Winklevoss Treasury Investments, LLC; Winklevoss Tyler Howard; Winklevoss Cameron Howard; Winklevoss Capital Management, LLC · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Option exercise (derivative) | 4,938,801 | $0.52 | $2.6M | Form 4 |
| 2026-10-12 | McEvoy William Patrick III · director, Chief Investment Officer, 10% owner | Option exercise (derivative) | 4,938,801 | $0.52 | $2.6M | Form 4 |
| 2026-09-25 | Oei Khing Djien · director | Open-market sale | 168,750 | $3.92 | $662K | Form 4 |
| 2026-09-23 | Martin Patricia A. · director | Open-market sale | 50,000 | $3.86 | $193K | Form 4 |
| 2026-08-26 | Dietz Thomas John · director | Open-market sale | 20,000 | $1.72 | $34K | Form 4 |
| 2026-08-21 | Zhang Kevin · Head of Mining | Award / grant (derivative) | 2,000,000 | — | — | Form 4 |